Swiss Biotech Stock News

Key Insights The considerable ownership by individual investors in Schweiter Technologies indicates that they...

Key Insights Tecan Group will host its Annual General Meeting on 10th of April Total pay for CEO Achim von Leoprechting...

Key Insights Galenica to hold its Annual General Meeting on 10th of April CEO Marc Werner's total compensation includes...

With a median price-to-sales (or "P/S") ratio of close to 1.6x in the Semiconductor industry in Switzerland, you could...

Key Insights Logitech International's estimated fair value is CHF61.55 based on 2 Stage Free Cash Flow to Equity With...

Key Insights Emmi's Annual General Meeting to take place on 10th of April Salary of CHF733.0k is part of CEO Ricarda...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Key Insights Comet Holding will host its Annual General Meeting on 10th of April CEO Stephan Haferl's total...

Montana Aerospace ( VTX:AERO ) Full Year 2024 Results Key Financial Results Revenue: €1.54b (up 6.7% from FY 2023). Net...

While Dätwyler Holding AG ( VTX:DAE ) might not have the largest market cap around , it received a lot of attention...

Bucher Industries AG ( VTX:BUCN ), is not the largest company out there, but it saw a double-digit share price rise of...

Key Insights Zurich Insurance Group will host its Annual General Meeting on 9th of April Salary of US$1.96m is part of...

Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shareholders won't be pleased to see that the share price has had a very...

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...

Key Insights VZ Holding will host its Annual General Meeting on 9th of April Salary of CHF700.0k is part of CEO Giulio...

Key Insights Given the large stake in the stock by institutions, Temenos' stock price might be vulnerable to their...

Roche Holding (SWX:ROG) experienced a 14% increase in share price over the last quarter, driven in part by several key developments. The MUSETTE Phase III trial results highlighted the strong efficacy of the approved 600 mg dose of OCREVUS for multiple sclerosis, reinforcing its position in the market. Additionally, the launch of a subcutaneous formulation and ongoing expansion in its neuromuscular portfolio, including advancements from its collaboration with Oxford BioTherapeutics, likely...

BKW AG ( VTX:BKW ) has announced that it will be increasing its dividend from last year's comparable payment on the 6th...

Julius Bär Gruppe AG ( VTX:BAER ) will pay a dividend of CHF2.60 on the 16th of April. This means the annual payment is...

Forbo Holding AG ( VTX:FORN ) has announced that it will pay a dividend of CHF25.00 per share on the 11th of April...

Key Insights Using the 2 Stage Free Cash Flow to Equity, ABB fair value estimate is CHF45.24 With CHF45.86 share price...

Zurich Insurance Group AG ( VTX:ZURN ) has announced that it will be increasing its dividend from last year's...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...

Walliser Kantonalbank ( VTX:WKBN ) Full Year 2024 Results Key Financial Results Revenue: CHF294.8m (flat on FY 2023...